HGS shareholders vow to challenge takeover by GSK
GlaxoSmithKline (GSK) reeled in its long-term drug development partner Human Genome Sciences, with an agreed takeover offer pitched at about $3bn (£1.9bn), though some HGS shareholders immediately said they would challenge the deal.
HGS directors were threatened with a class action lawsuit alleging they breached their duty to shareholders by accepting the GSK offer, which was upped to $14.25 a share – better than the $13 originally tabled. At that price, the deal is double the $7.17 HGS shares were fetching before GSK's bid was disclosed in April.
It has taken the UK drugs giant several months to land its prize, after a battle that began when the US firm rejected its initial offer of $2.6bn in April. As HGS began scrabbling for rival offers to trump GSK, the British company said that it would make its deal hostile.
In the end, the choice facing HGS management was not between GSK and other bidders but between GSK and going it alone.
No other suitors emerged, because of the high cost of unwinding HGS's deep existing relationship with GSK.
Sir Andrew Witty, GSK's chief executive, called it "a mutually beneficial agreement" and the next logical step in the long relationship between the two companies.
Annual cost savings could top $200m by 2015, GSK claimed.
The two companies began working together almost 20 years ago, when GSK paid $125m in 1993 to establish a research partnership.
HGS was one of the first biotech companies to emerge from the early 1990s push to map all of the genes in the human body.
GSK and HGS jointly sell a drug for lupus that they developed together, Benlysta, the first new treatment for the disease to have emerged in half a century.
The drug's sales have so far been sluggish, though analysts remain optimistic and there is also a pipeline of additional and potentially lucrative products.
These include drugs for diabetes and heart disease, in which GSK and HGS share a financial interest.
Thomas Watkins, chief executive of HGS, said that the company has had "a long and productive working relationship with GSK, and together we will be uniquely positioned to achieve the full potential of Benlysta and other products in our pipeline for the benefit of those battling serious disease around the world".
The law firm Levi & Korsinsky last night announced an investigation into potential breaches of fiduciary duty by HGS directors and into whether the company should have held out for a higher price.
The deal is the latest in a busy sector, as drug companies fight for new revenue as traditional moneyspinners come off patent protection.
Last month, Bristol-Myers Squibb said it would pay $5.3bn for diabetes drug maker Amylin.
- 1 Saudi Arabia mosque bombing: Two volunteer security guards hailed as heroes for stopping Isis suicide bomber reaching worshippers
- 2 Maisie Williams has an excellent message for one confused fan
- 3 Puerto Rico, island of lost dreams: People are leaving the debt-hit territory in droves as near neighbour Cuba's star rises
- 4 Tampon tax scrapped in Canada after petition convinces conservative government
- 5 Kate Moss on the naked Calvin Klein shoot and the obsession that ended her relationship
Saudi Arabia mosque bombing: Two volunteer security guards hailed as heroes for stopping Isis suicide bomber reaching worshippers
Maisie Williams has an excellent message for one confused fan
Archaeologists discover 2,400-year-old gold bongs in Russia
Tampon tax scrapped in Canada after petition convinces conservative government
Migrants in Kos: Photos show real tragedy after British tourists complain of 'awkward' holidays
EU referendum: David Cameron's rules are a 'democratic disgrace', says French-born Scottish politician set to be denied a vote
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
A nation of inequality: How the UK is failing to feed its most vulnerable people
Australian man punched in the face for defending Muslim women from abuse on train
David Starkey 'tells Amal Clooney to shut up and stop over-promoting human rights'
EU referendum: David Cameron to deny EU migrants and under-18s the chance to vote
iJobs Money & Business
£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...
£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...
£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...